Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel ...

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in ...

Medically reviewed by Doru Paul, MD Leukemia is a cancer that changes blood cells. It usually develops in the bone marrow, ...

Triplet Regimen Yields Promising Response in Advanced-Phase Chronic Myeloid Leukemia Sep. 17, 2024 — According to new research, 80% of patients with previously untreated or relapsed/refractory ...

A Yale School of Medicine team has created lists of criteria to help clinicians determine when next-generation sequencing ...

Terns Pharmaceuticals Inc.’s stock was soaring 14% Wednesday, as analysts cheered positive data released a day earlier on a ...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...

The first comprehensive map of the dramatic changes that take place in the blood system over the course of the human lifetime could have implications for the treatment of acute myeloid leukemia and ...

Updated 96-week data from the ASC4FIRST trial show asciminib significantly outperforms standard TKIs in major molecular ...